Dr. Ruslana Bryk's lab focuses on developing new antibiotics to combat tuberculosis (TB) and non-tuberculous mycobacterial (NTM) diseases. They study a specific target in bacteria, lipoamide dehydrogenase (Lpd), to discover and optimize new drug candidates that can effectively kill these pathogens. The lab aims to understand the mechanisms of these inhibitors, improving their effectiveness and addressing the rise of drug-resistant strains.

Dr. John P. Moore's lab focuses on understanding how the immune system can effectively combat HIV-1, the virus that causes AIDS. By studying broadly neutralizing antibodies (bNAbs), the lab aims to improve both vaccine strategies and treatments for HIV-1 infection. The research involves innovative methods to analyze antibody behavior and viral interactions to enhance our knowledge of immunity against HIV-1.

Dr. Gang Lin's research lab focuses on developing innovative proteasome inhibitors to treat aggressive cancers like triple negative breast cancer and to combat drug-resistant malaria. By understanding protein degradation mechanisms in cells, his team aims to create safer and more effective therapeutics that can address significant health challenges in both oncology and infectious diseases.

Dr. Xiaojing Ma's research lab at Weill Medical College focuses on understanding the role of a gene called UBR5 in cancer, particularly breast and ovarian cancer. By studying how UBR5 affects tumor growth and immune response, the lab aims to uncover new therapeutic strategies that could help treat aggressive types of breast cancer that resist current treatments. The findings from this research could significantly improve patient outcomes by targeting specific biological processes that drive cancer progression.

Dr. Kirk Deitsch's research lab focuses on understanding how malaria parasites change their outer surfaces to evade the immune system. By studying the molecular mechanisms behind this process, the lab aims to find new ways to combat malaria, particularly in young children who are at high risk of severe disease. This work not only enhances our understanding of malaria but also seeks to develop better treatments.

Dr. Dirk Schnappinger's lab at Weill Medical College focuses on understanding tuberculosis (TB), a major global health issue. The lab investigates the mechanisms of new antibiotics called nitroimidazoles, which are essential for treating drug-resistant TB. By studying the genetics and metabolism of the TB bacteria, the team aims to enhance treatment strategies and develop more effective drugs.

Dr. Sabine Ehrt's lab focuses on understanding the role of M. tuberculosis (Mtb) and its metabolism during infection to aid in developing new tuberculosis drugs. The research particularly examines how different environments within the human body affect Mtb's survival and growth, especially regarding its carbon source requirements. By studying drug targets in animal models that mirror human conditions, her lab aims to find innovative therapeutic approaches to combat tuberculosis, a significant global health threat.